CTOs on the Move


 
ASDI is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.asdi.net
  • 601 Interchange Blvd
    Newark, DE USA 19711
  • Phone: 302.266.6891

Executives

Name Title Contact Details

Similar Companies

GeneGo bioinformatics software

GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boston Immune Technologies and Therapeutics

Boston Immune Technologies & Therapeutics based Inc

Mesa Biotech

Accurate. Accessible. Actionable. Simplifying PCR, transforming healthcare.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

Soley Therapeutics

Soley Therapeutics is a San Francisco-based, privately-held biotechnology company that is combining artificial intelligence with unique proprietary molecular and cellular response detection for discovering and developing new efficacious drugs, using image acquisition-based approaches. We have translated decades of research by Soley`s co-founders on cell-responses to perturbations and resulting information-flow within the cell, into quantifiable high-resolution imaging to identify and accelerate the development of novel therapeutic molecules for complex diseases.